The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

November 25, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rituximab-abbs Available in the U.S.
A Truxima (rituximab-abbs) injection is now available in the U.S. to treat patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and other cancers.1 Truxima is biosimiliar to Rituxan (rituximab). In May 2019, the U.S. Food and Drug Administration (FDA) approved Truxima for all of Rituxan’s oncology indications. The approval was based on a comprehensive review of data, including analytical characterization, nonclinical data, clinical pharmacology, immunogenicity, clinical efficacy and safety.

You Might Also Like
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Promising for RA in Phase 3 Study
  • Upadacitinib Promising for RA Patients
Also By This Author
  • EU Approves Certolizumab Pegol for Pregnant & Nursing Patients

Due to a patent settlement, an FDA submission is pending for Truxima to be used to treat rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. A license from Genentech, the maker of Rituxan, that would expand Truxima’s label to include these indications is also pending and expected in the second quarter of 2020.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Upadacitinib Studied for PsA
On Oct. 31, researchers announced the results of SELECT-PsA 2, a phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled study. The study evaluated the safety and efficacy of upadacitinib in adults with active psoriatic arthritis (PsA).2 To be enrolled in the study, patients had to have a history of inadequate response to at least one biologic disease-modifying anti-rheumatic drug (bDMARD). Patients were randomized to receive 15 or 30 mg of upadacitinib or placebo, followed by either 15 or 30 mg of upadacitinib at Week 24.

The primary endpoint was the percentage of patients who achieved an ACR20 response at Week 12. Patients in both upadacitinib groups met the primary study endpoint. The results: 57% of 15 mg upadacitinib-treated patients achieved an ACR20 response, and 64% of 30 mg upadacitinib-treated patients achieved an ACR20 response. Only 24% of placebo-treated patients achieved an ACR20 response.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Secondary study endpoints included a change from baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI), the proportion of patients who achieved ACR50 and ACR70 responses at Week 12, the proportion of patients who achieved Psoriasis Area and Severity Index (PASI) 75 at Week 16 and the proportion of patients who achieved minimal disease activity at Week 24.

At Week 16, a PASI 75 response was achieved by 52% of 15 mg upadacitinib-treated patients, 57% of 30 mg upadacitinib-treated patients and 16% of placebo-treated patients. At Week 24, 25% of 15 mg upadacitinib-treated patients, 29% of 30 mg upadacitinib-treated patients and 3% of placebo-treated patients achieved minimal disease activity. Significantly more upadacitinib-treated patients achieved ACR50 and 70 responses than did placebo-treated patients (P<0.0001).

No new safety signals were identified during the study.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Teva Pharmaceutical Industries Ltd. News release: Teva and Celltrion announce the availability of Truxima (rituximab-abbs) injection, the first biosimilar to Rituxan (rituximab) in the U.S. 2019 Nov 7.
  2. AbbVie Inc. News release: Rinvoq (upadacitnib) meets primary and all ranked secondary endpoints in phase 3 study in psoriatic arthritis. 2019 Oct 31.

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: Cancer, non-Hodgkin’s lymphoma, psoriatic arthritis, rituximab, rituximab-abbs, upadacitinib

You Might Also Like:
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Promising for RA in Phase 3 Study
  • Upadacitinib Promising for RA Patients
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.